PREVACID Drug Patent Profile

Which patents cover Prevacid, and what generic alternatives are available?

Prevacid is a drug marketed by Takeda Pharms Usa, Takeda Pharms Na, and Perrigo Pharma Intl. and is included in six NDAs.

The generic ingredient in PREVACID is lansoprazole; naproxen. There are fifty-six drug master file entries for this compound. Additional details are available on the lansoprazole; naproxen profile page.

Summary for PREVACID

US Patents:	0
Applicants:	3
NDAs:	6
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	162
Clinical Trials:	42
Patent Applications:	4,597
Drug Prices:	Drug price information for PREVACID
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PREVACID
What excipients (inactive ingredients) are in PREVACID?	PREVACID excipients list
DailyMed Link:	PREVACID at DailyMed

See drug prices for PREVACID

See drug sales revenues for PREVACID

Recent Clinical Trials for PREVACID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Janssen Research & Development, LLC	Phase 1
McGill University Health Center	Phase 4
McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4

See all PREVACID clinical trials

Pharmacology for PREVACID

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Proton Pump Inhibitors
Physiological Effect	Inhibition Gastric Acid Secretion

Paragraph IV (Patent) Challenges for PREVACID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PREVACID	Delayed-release Orally Disintegrating Tablets	lansoprazole	15 mg and 30 mg	021428	1	2006-12-27
PREVACID	Delayed-release Pellets/Capsules	lansoprazole	15 mg and 30 mg	020406		2005-12-05

US Patents and Regulatory Information for PREVACID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	PREVACID	lansoprazole	CAPSULE, DELAYED REL PELLETS;ORAL	020406-001	May 10, 1995		DISCN	Yes	No
Perrigo Pharma Intl	PREVACID 24 HR	lansoprazole	CAPSULE, DELAYED REL PELLETS;ORAL	022327-001	May 18, 2009		OTC	Yes	Yes
Takeda Pharms Na	PREVACID	lansoprazole	FOR SUSPENSION, DELAYED RELEASE;ORAL	021281-002	May 3, 2001		DISCN	No	No

Expired US Patents for PREVACID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	PREVACID	lansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	021428-002	Aug 30, 2002
Takeda Pharms Usa	PREVACID	lansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	021428-002	Aug 30, 2002
Takeda Pharms Na	PREVACID	lansoprazole	FOR SUSPENSION, DELAYED RELEASE;ORAL	021281-001	May 3, 2001

International Patents for PREVACID

See the table below for patents covering PREVACID around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	42554
Australia	4589585
Australia	570130

Supplementary Protection Certificates for PREVACID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0174726	SPC/GB94/011	United Kingdom		SPC/GB94/011, EXPIRES: 20051210
0174726	93C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
0328535	96C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209

PREVACID (lansoprazole) market dynamics and financial trajectory: pricing, volume, exclusivity clock, and competitive pressure

Last updated: July 22, 2026

Prevacid (lansoprazole) is a long-established, small-molecule branded PPI that has been heavily competed by multiple generic entrants in the US. The market today is dominated by generic lansoprazole across retail and institutional channels, with branded sales shrinking to niche share. The financial trajectory for “Prevacid” as a brand has therefore been a steady downtrend driven by: (1) earlier patent and exclusivity expiry, (2) multiple FDA-approved generics, and (3) continued erosion from price compression in the PPI class.

How did Prevacid’s branded sales perform after generic competition?

Branded Prevacid’s financial trajectory is best read through a simple lens: once generic lansoprazole achieved broad formulary adoption, branded volume decayed rapidly and remaining revenue shifted to higher-priced channel mix that could not offset gross-to-net pressure. For analytics and investment models, the post-generic period behaves like a classic “legacy brand” profile: declining net sales, reduced marketing intensity, and a growing gap between originator gross price and effective net realized price due to rebates, contracting, and payer steerage toward generics.

What does the “brand vs generic” split imply for revenue?

For lansoprazole, the economics follow standard US payer behavior:

• Pharmacy benefit managers and health plans move to lowest-cost AA/AB-rated generics quickly after availability.
• Retail brands retain only limited market share via prescriber preference, grandfathering, and convenience formulations where generics match closely.
• Institutional formularies tend to standardize to generic PPIs unless a distinct clinical protocol exists that favors a specific brand or package.

When did Prevacid lose exclusivity in the US?

Prevacid is no longer on primary US exclusivity. The competitive reality is that lansoprazole generics are long past initial exclusivity periods and have multiple approved products. Any remaining “protection” at this stage is typically fragmented into later-life patents (formulation, method-of-use, device/packaging, or specific delivery systems), which does not restore brand-level exclusivity once AB-rated generic lansoprazole is broadly authorized and stocked.

How does that affect market timing and generic launch risk?

For a legacy PPI like lansoprazole:

• Near-term “launch window” risk is low because multiple generics already exist.
• The incremental risk shifts from “will generics launch?” to “will new entrants undercut price further?” and “will specific sub-markets move from one generic SKU to another based on contract economics?”

What is the Orange Book status of PREVACID?

Prevacid’s Orange Book listings include drug substance and formulation patents historically associated with lansoprazole products. Current competitive conditions indicate that any listed Orange Book protection tied to the original branded product set has not prevented generic competition for years. Practically, the Orange Book relevance for investors now is less about timing an exclusivity end point and more about mapping any residual patent claims that could affect specific dosage forms, strengths, or versions (for example, delayed-release capsules vs other presentations).

Do Orange Book patents still matter for branded Prevacid today?

Residual patents can matter if they:

• Cover a specific delivery system or formulation variant that is not fully replicated by all generics.
• Support litigation that constrains one manufacturer’s product at launch.
• Protect a product line that remains branded in limited channels or under specific contracts.

Given the entrenched generic landscape, these impacts are usually narrow and do not reverse the broader brand decline.

What patent and litigation landscape has shaped the generic curve for lansoprazole?

The branded-to-generic transition in lansoprazole is the result of early patent expiry and subsequent generic entry rather than late-stage “single-event” litigation delays typical of newer drugs. Market behavior indicates generic saturation rather than a prolonged “bottleneck” effect.

How do Paragraph IV challenges factor in today?

For a mature molecule like lansoprazole:

• Paragraph IV challenges are no longer the main determinant of brand economics.
• Competitive pressure is dominated by ongoing price competition among existing generic filers and contract-driven supply dynamics.

How do PPI class dynamics affect Prevacid pricing and volume?

Prevacid sits in a PPI class where:

• Many molecules have mature generic competition.
• Payer formularies favor low-cost therapy.
• Switching cost is low because PPIs are therapeutically interchangeable in most indications.

What drives price erosion across the PPI category?

Key forces:

• Wholesale and retail channel contracting around lowest net cost.
• Frequent substitution at the pharmacy counter.
• Broad AB-rating alignment across multiple generic PPIs (omeprazole, pantoprazole, esomeprazole, lansoprazole, etc.).
• Increased use of step-therapy protocols and guideline-based prescribing.

For Prevacid, those forces translate into sustained net price pressure that generic lansoprazole products exploit through cost-based contracting.

What are the main competitive products against Prevacid?

Competitive substitution is within-class and within-molecule:

• Other generic PPIs for GERD, dyspepsia, and ulcer prophylaxis.
• Generic lansoprazole products from multiple manufacturers.

How does competition shift channel strategy?

As generic options expand, branded originators typically:

• Reduce promotional spend.
• Focus on remaining “soft” share segments, often where patient history, prescriber familiarity, or formulary exceptions maintain some brand preference.
• Manage supply to avoid channel gaps that would accelerate brand share loss.

How do revenues for “Prevacid” differ from revenues for lansoprazole generics?

Branded Prevacid revenue is constrained by:

• Gross-to-net compression (rebates and contracting).
• Lower volume share once payers prefer generics.
• Limited ability to raise price due to AA/AB substitution and competition from multiple SKUs.

Generic revenues are constrained by:

• Narrower gross margins.
• Lower net price per unit due to auction-like contracting.
• Manufacturing and supply chain efficiency requirements to remain profitable.

This creates an industry pattern where branded revenue continues to fall while generic sector profit depends heavily on cost curve positioning and contract wins.

What is the financial trajectory likely to look like for remaining branded Prevacid exposure?

For long-mature PPIs:

• The “brand financial trajectory” is not an upside curve. It is a decline curve that may stabilize at a reduced level in specific subchannels.
• Any stabilization typically reflects distribution and contracting inertia, small formulation-specific niches, or payer-specific switching frictions.

Prevacid’s trajectory is aligned with this profile: continued downward pressure with modest stabilization if any niche remains.

What manufacturing and supply dynamics matter for lansoprazole market shares?

At scale, supply chain execution determines outcomes:

• Generic lansoprazole producers compete for contracts with reliable volume and low out-of-stock risk.
• API and formulation costs drive survival of higher-cost producers.
• Capacity constraints or API interruptions can temporarily raise net prices, but sustained brand re-expansion does not follow, because payers keep switching suppliers when available.

What commercial metrics should be used to track Prevacid’s market decline accurately?

For business monitoring, the most decision-relevant metrics are:

• US retail and institutional net sales trends for the branded product name “Prevacid” (not just molecule total).
• Prescription share by pack and strength to capture AA vs AB substitutions.
• Average wholesale price and net price indices at the PBM and plan-contract level.
• Claims-based persistence after switching from branded to generic PPIs.
• Contract win rate and rebidding cycles among generic manufacturers.

How does Prevacid compare to other mature PPIs in financial profile?

Prevacid’s competitive situation is consistent with the generic maturity of other PPIs:

• Similar clinical value, low differentiation.
• Similar payer switching behavior.
• Similar price compression after generic penetration.

If any differences exist, they typically come from:

• Formulation nuances (capsule vs other delivery).
• Specific payer preference lists for certain generics due to contracting and supply reliability.
• Legacy brand loyalty patterns in certain prescriber segments.

Key Takeaways

• Prevacid’s financial trajectory is a long decline shaped by US generic saturation of lansoprazole and persistent payer-driven substitution.
• Residual Orange Book and patent assets, if any, are unlikely to restore brand-level exclusivity in a market where multiple AB-rated generics exist.
• PPI class economics dominate: low switching cost, formulary steerage to lowest net cost, and continued price compression.
• Current market dynamics are supplier- and contracting-driven rather than exclusivity-driven.

FAQs

1) What drives branded PPI (including Prevacid) net sales decline after generic lansoprazole launches?
Net price compression from PBM contracting, switching to AB-rated products, and contracting inertia that only delays substitution in small segments.

2) Are there specific Prevacid dosage forms that face different generic competition risk?
Yes. Competitive intensity can vary by strength, presentation, and packaging, where not all generics enter simultaneously or with identical coverages.

3) Do Orange Book patents still affect generic lansoprazole pricing and availability?
They can affect individual manufacturers or specific presentations, but they do not typically prevent broad class substitution once multiple AB-rated products are established.

4) How do PPI step-therapy and formulary tiers affect Prevacid performance?
They reduce prescriber ability to initiate branded PPIs and increase substitution at renewal, accelerating volume erosion.

5) What metrics best predict future market share changes for generic lansoprazole?
Contract win rates, prescription share by SKU, persistence after formulary switches, and supply reliability/out-of-stock rates.

---

References (APA)

1. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Prescription Drug User Fee resources and drug approval/patient labeling databases (for product and regulatory history navigation). https://www.fda.gov/drugs

DrugChatter Q&A for PREVACID

Generic name for prevacid?
Difference between prevacid and prilosec?